GE HealthCare to Buy Sofie Biosciences for $945 Million

GE HealthCare said it will buy privately held Sofie Biosciences for $945 million in cash, according to Kfgo’s report of a Reuters story published October 5.

Reuters reported that the acquisition is intended to strengthen GE HealthCare’s ability to manufacture and distribute PET imaging drugs. The transaction places radiopharma capabilities at the center of the announced deal.

Deal Centers on Radiopharma Capabilities

Sofie Biosciences is a privately held company, Reuters reported. GE HealthCare’s planned cash purchase would add capabilities connected to PET imaging drugs, including their manufacture and distribution.

The reported consideration is $945 million in cash. Reuters characterized the move as one that would strengthen GE HealthCare’s radiopharma business through expanded ability to manufacture and distribute PET imaging drugs.

The Kfgo report does not provide further details about the transaction beyond the announced purchase price, the cash consideration, and the stated focus on PET imaging drug capabilities.

Relevance Across Medical Imaging

The announcement links a medical device maker with the manufacturing and distribution of PET imaging drugs. For professionals working across medical imaging, the reported rationale highlights the operational connection between imaging and radiopharma capabilities.

Reuters reported that GE HealthCare is pursuing Sofie Biosciences to strengthen those capabilities. The announcement specifically identifies PET imaging drugs as the area in which manufacturing and distribution would be enhanced.

Reported Transaction Details

• Buyer: GE HealthCare
• Target: Sofie Biosciences
• Consideration: $945 million in cash
• Company status: Sofie Biosciences is privately held
• Stated purpose: Strengthen the manufacture and distribution of PET imaging drugs
• Source: Reuters, as reported by Kfgo

GE HealthCare’s announcement is focused on strengthening its radiopharma business. Additional transaction details were not included in the Kfgo report of the Reuters story.